Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
Authors
Kirsten C. Morley (ORCID: https://orcid.org/0000-0002-0868-9928)
Adrian Dunlop (ORCID: https://orcid.org/0000-0003-2394-5966)
Department of Health and Aged Care, Australian Government
Otsuka Pharmaceutical
Substance Abuse and Mental Health Services Administration
Medical Research Council
National Health and Medical Research Council
National Institute of Mental Health
National Institute on Drug Abuse
National Center for Advancing Translational Sciences
Daiichi Sankyo Europe
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
Kirsten C. Morley, Adrian Dunlop, Brendan Clifford, Nadine Ezard et al.
Journal
BMJ Open
Topics
Opioid Use Disorder Treatment
article
Trial protocol of an open-label pilot study of oral naltrexone–bupropion combination pharmacotherapy for the treatment of methamphetamine use disorder (the NABU trial)
Kirsten C. Morley, Adrian Dunlop, Brendan Clifford, Nadine Ezard, Krista J. Siefried, Michael Christmass, STEVEN J. SHOPTAW, Didier Jutras‐Aswad, Liam Acheson, Carl I. Moller, Paul Haber, Nicholas Lintzeris, Madhukar H. Trivedi, Jonathan Brett
article en
Abstract
No abstract available for this paper.
Publication Tag
BMJ OpenVol. 15(2)
Institutions
The University of Sydney (AU), University of California, Los Angeles (US), Royal Prince Alfred Hospital (AU), UNSW Sydney (AU), St Vincent's Hospital Melbourne (AU), St Vincent's Hospital Sydney (AU), St Vincent's Clinic (AU), North Metropolitan Health Service (AU), National Centre for Clinical Research on Emerging Drugs (AU), Centre Hospitalier de l’Université de Montréal (CA), South Eastern Sydney Local Health District (AU), Hunter New England Local Health District (AU), East Metropolitan Health Service (AU), Université de Montréal (CA), University of Newcastle Australia (AU), The University of Texas Southwestern Medical Center (US)
Funders
American Foundation for Suicide Prevention, Biogen, Patient-Centered Outcomes Research Institute, Indivior, ACADIA Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Otsuka America, University of Oxford, Department of Health and Aged Care, Australian Government, Otsuka Pharmaceutical, Substance Abuse and Mental Health Services Administration, Medical Research Council, National Health and Medical Research Council, National Institute of Mental Health, National Institute on Drug Abuse, National Center for Advancing Translational Sciences, Daiichi Sankyo Europe